| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| Other Sizes |
| Targets |
The primary target of Ligustrazine includes TFAM (mitochondrial transcription factor A). It acts as a blocker of TFAM degradation. Ligustrazine also has anti-inflammatory activity and is used to treat a number of illnesses, including liver damage, diabetes, cancer, and coronary heart disease.
|
|---|---|
| ln Vitro |
For about 40 years, ligentazine has been extensively utilized in my nation to treat cardiovascular and cerebrovascular illnesses. because it works well in many systems, including the heart. Ligustrazine is also used to treat a number of illnesses, including liver damage, diabetes, cancer, and coronary heart disease [1].
In vitro, Ligustrazine has protective effects against injured ECV304 cells. It has anti-inflammatory activity and inhibits TFAM degradation. The compound's effects on cell viability and function have been demonstrated in various cell lines. |
| ln Vivo |
In vivo, Ligustrazine is used to treat a number of illnesses, including liver damage, diabetes, cancer, and coronary heart disease. It has long been used in China for the treatment of cardiovascular problems. The compound has potential nootropic and anti-inflammatory activities.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Ligustrazine are not typically performed, as it does not have a single specific target. Its anti-inflammatory activity can be assessed by measuring the production of inflammatory cytokines in immune cells. Its effects on TFAM expression can be studied by Western blotting and qPCR.
|
| Cell Assay |
In vitro cell-based assays for Ligustrazine are performed using various cell lines, such as ECV304 cells. Cells are treated with the compound, and cell viability, apoptosis, and inflammatory responses are assessed. The compound's effects on TFAM expression are analyzed.
|
| Animal Protocol |
In vivo animal experiments for Ligustrazine are conducted using rodent models of liver damage, diabetes, cancer, and coronary heart disease. The compound is administered orally or intraperitoneally, and disease parameters are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Ligustrazine indicate that it has a molecular weight of 136.19 and a molecular formula of C8H12N2. The CAS number is 1124-11-4. The IUPAC name is 2,3,5,6-Tetramethylpyrazine. It is a solid at room temperature. Storage at room temperature is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Ligustrazine indicate that it is generally well-tolerated. As a natural product, it has a favorable safety profile. However, its safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only.
|
| References |
|
| Additional Infomation |
Tetramethylpyrazine is a type of pyrazine compound with a structure in which all four hydrogen atoms in the pyrazine molecule are replaced by methyl groups. It is an alkaloid extracted from Ligusticum wallichii. Tetramethylpyrazine possesses various activities, including antitumor activity, inhibition of apoptosis, neuroprotection, vasodilatory activity, inhibition of platelet aggregation, and its role as a bacterial metabolite. It belongs to the pyrazine alkaloid class. It has been reported that 2,3,5,6-tetramethylpyrazine exists in Francisella tularensis, Camellia sinensis, and other organisms with relevant data.
Other information: Ligustrazine is also known as Tetramethylpyrazine, Chuanxiongzine, and TMP. It is a naturally occurring alkylpyrazine isolated from Ligusticum chuanxiong. The compound has protective effects against injured ECV304 cells. Its CAS number is 1124-11-4. |
| Molecular Formula |
C8H12N2
|
|---|---|
| Molecular Weight |
136.198
|
| Exact Mass |
136.1
|
| CAS # |
1124-11-4
|
| Related CAS # |
Ligustrazine hydrochloride;76494-51-4
|
| PubChem CID |
14296
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
192.7±35.0 °C at 760 mmHg
|
| Melting Point |
77-80 °C(lit.)
|
| Flash Point |
71.6±17.6 °C
|
| Vapour Pressure |
0.7±0.4 mmHg at 25°C
|
| Index of Refraction |
1.504
|
| LogP |
1.56
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
87.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(N=C(C(=N1)C)C)C
|
| InChi Key |
FINHMKGKINIASC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3
|
| Chemical Name |
2,3,5,6-tetramethylpyrazine
|
| Synonyms |
Ligustrazine; Chuanxiongzine; 2,3,5,6-Tetramethylpyrazine; TETRAMETHYLPYRAZINE; 1124-11-4; Ligustrazine; Chuanxiongzine; Tetramethylpyrazine; TMP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~367.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.3421 mL | 36.7107 mL | 73.4214 mL | |
| 5 mM | 1.4684 mL | 7.3421 mL | 14.6843 mL | |
| 10 mM | 0.7342 mL | 3.6711 mL | 7.3421 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
